Antibody response with SARS-CoV-2 inactivated vaccine (CoronaVac) in Turkish geriatric population

Creative Commons License

Bas A. O., HAFIZOĞLU M., Akbiyik F., GÜNER OYTUN M., Sahiner Z., CEYLAN S., ...More

AGE AND AGEING, vol.51, no.5, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 51 Issue: 5
  • Publication Date: 2022
  • Doi Number: 10.1093/ageing/afac088
  • Journal Name: AGE AND AGEING
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, ASSIA, Abstracts in Social Gerontology, AgeLine, BIOSIS, CAB Abstracts, CINAHL, EMBASE, MEDLINE, PAIS International, Public Affairs Index
  • Keywords: SARS-CoV-2, sinovac, coronavac, neutralising antibody, anti-Spike IgG, older people, COVID-19 VACCINE, IMMUNOGENICITY, FRAILTY, INDEX, RISK
  • Hacettepe University Affiliated: Yes


Background Sars-CoV-2 infection influences older individuals at the forefront, and there is still limited data on the COVID-19 vaccine response in the geriatric population. This study aimed to assess antibody response after vaccination with SARS-CoV-2 inactivated vaccine and examine possible factors affecting this response in a geriatric population. Methods individuals who have been on at least the 28th day after the second dose of the COVID-19 vaccine were included. Comprehensive geriatric assessment tools and the Clinical Frailty Scale were performed. SARS-CoV-2 spike-specific IgG antibodies were detected and, levels >= 1 U/ml were defined as seropositive, Results a total of 497 patients were included and divided into three groups according to the days past after the second dose of the vaccine (Group 1: 28-59 days, Group 2: 60-89 days and Group 3: 90 days and more). Groups included 188, 148 and 171 patients, respectively. Seropositivity rate in each group was 80.9,73.2 and 57.3%, respectively. In Groups 1 and 2, Charlson Comorbidity Index score was higher in the seronegative group (P = 0.023 and P = 0.011, respectively). In Group 3, the prevalence of frailty was significantly higher in the seronegative group (P = 0.002). Conclusion to the best of our knowledge, this is the first study assessing the antibody response after vaccination with Sars-CoV 2 inactivated vaccine in the Turkish geriatric population. Moreover, this is the first study revealing the relationship between antibody response and frailty. Larger studies are needed to confirm the antibody response duration and the association between frailty and COVID-19 vaccine response.